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This study evaluated the levels of two amino acid derivatives taurine and spermine in
first-episode psychosis (FEP) patients and their response to antipsychotic treatment.
The levels of taurine and spermine were significantly up-regulated in antipsychotic-naïve
FEP patients compared to control subjects (CS). Treatment of FEP patients with
antipsychotic drugs significantly reduced the positive symptoms of schizophrenia. This
positive effect was accompanied by a significant reduction of taurine and spermine to
the levels measured in CS. General linear model was used to establish associations of
taurine and spermine with the levels of cytokines and growth factors, measured in our
previous experiments using the same study sample. There was a strong association
between taurine and epidermal growth factor (EGF). Both biomarkers significantly
correlated with the disease symptoms as well as with the effectiveness of antipsychotic
treatment. Accordingly one can conclude that taurine and EGF belong to the signature
of FEP. Most probably they reflect altered oxidative stress and corrupted function of
N-methyl-D-aspartate (NMDA) receptors in FEP.
Keywords: taurine, spermine, cytokines, growth factors, epidermal growth factor, NMDA receptors, first-episode
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INTRODUCTION
There is increasing trend to implicate inflammatory processes, elevated oxidative stress and
metabolomic alterations to the pathophysiology of psychotic disorders. Recently we demonstrated a
link between epidermal growth factor (EGF) and first-episode psychosis (FEP) (Haring et al., 2015).
The levels of EGF were significantly upregulated in FEP patients compared to control subjects
(CS). Treatment of FEP patients with antipsychotic drugs improved the clinical symptoms and
returned EGF to the levels of CS (Haring et al., 2015). Recent pre-clinical research demonstrated
that treatment of rodents with EGF induces oxidative stress (Nagano et al., 2015). Tang et al.
(2015) showed that EGF receptor signaling upregulates surface expression of the GluN2B-
containing N-methyl-D-aspartate (NMDA) receptor and contributes to long-term potentiation
in the hippocampus. Moreover, NMDA receptor agonists reverse impaired psychomotor and
cognitive functions associated with hippocampal heparin-binding EGF-like growth factor (Hbegf)
deficiency in mice (Sasaki et al., 2015). It is noteworthy that the recent opinion of Hardingham
and Do (2016) links the development of schizophrenia (SCZ) with alterations in NMDA receptor
function and oxidative stress. These factors have been separately linked to SCZ pathogenesis, but
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evidence now suggests that they are mechanistically
interdependent and contribute to a common SCZ-associated
pathology (Hardingham and Do, 2016).
A clinical study performed by Samuelsson et al. (2013)
established significantly elevated levels of taurine in patients
suffering from chronic SCZ. Taurine is a sulfonated beta
amino acid derived from methionine and cysteine metabolism,
and it is the most abundant free amino acid in humans
and plays an important role in several essential biological
processes such as bile acid conjugation, maintenance of calcium
homeostasis, osmoregulation, and membrane stabilization
(Marcinkiewicz and Kontny, 2014). In addition, to functioning
as a neurotransmitter and an inhibitory neuromodulator in
the central nervous system (Oja and Saransaari, 1996), taurine
may also attenuate apoptosis and function as neuroprotectant,
antioxidant and immunomodulator (Almarghini et al., 1991;
Redmond et al., 1998). Indeed, taurine has been shown to
possess potent neuroprotective capacities, including inhibition
of glutamate-induced neurotoxicity (Wu et al., 2009). It is
apparent that taurine affects the formation of reactive oxidative
species (Zhang et al., 2014). Like EGF, taurine targets the
GluN2B-containing NMDA receptor subtype (Chan et al., 2015).
Besides that there is considerable evidence that some effects of
taurine need the presence of spermine. The effect of taurine
on 3H-MK801 binding, an antagonist of NMDA receptors, was
apparent only in the presence of spermine (Chan et al., 2013).
Spermine belongs to polyamines and it is formed from the
amino acid ornithine. Spermine reduces damage due to reactive
oxygen species, permits correct current flow through inwardly
rectifying K+ channels, controls activity of brain glutamate
receptors involved in learning and memory, and affects growth
response (Pegg, 2014). Spermine binds to polyamine sites located
on GluN2B subunits (Sirrieh et al., 2015). Spermine binding
to the extracellular portion of the NMDA receptor results in
an increase in apparent glycine affinity (Williams et al., 1994).
On the other hand, the gastro-protective effect of taurine also
involves interaction with spermine (Motawi et al., 2007).
Taken together, an apparent link exists between EGF, taurine
and spermine at least on the level of oxidative stress and
regulation of NMDA receptors via GluN2B subunit. Therefore,
the main goal of the present study was to measure the serum
levels of taurine and spermine in the same samples in which
we have previously described alterations in cytokine and growth
factors levels (Haring et al., 2015). For that purpose, additional
serum samples from the same participants were used. This
approach allows us to compare taurine and spermine levels
with EGF and other cytokines/growth factors measured in the
previous study. First, the levels of taurine and spermine were
compared between FEP patients and CS. Second, the effect of
7-months antipsychotic treatment on clinical symptoms, taurine
and spermine levels was evaluated in FEP patients. Subsequently,
correlations between taurine and spermine, and previously
measured cytokines and growth factors (Haring et al., 2015) were
analyzed. Finally, to estimate the relationships among variables,
we used general linear models (GLM). Based on the study of
Haring et al. (2015) we included EGF, IL-1β, IL-2, IL-4, and IL-6
in addition to taurine and spermine into the regression models to
establish effects of FEP and antipsychotic treatment on the serum
levels of the biomarkers.
MATERIALS AND METHODS
Participants
Patients’ data for the present investigation were obtained from
an ongoing longitudinal Estonian first-episode psychosis study.
Thirty-eight FEP patients were recruited from the Psychiatric
Clinic of Tartu University Hospital, Estonia. The patients fulfilled
the following inclusion criteria: age between 18 and 45; they
had experienced a first psychotic episode; the duration of
their untreated psychosis had been less than 3 years; they had
received no antipsychotic treatment before their first contact
with the medical services for psychosis. Patients were excluded
from the study if they had psychotic disorders owing to a
general medical condition or had substance induced psychosis.
FEP diagnoses were based on clinical interviews according
to the International Classification of Diseases, Tenth Edition
(ICD-10) (World Health Organization, 1992) criteria. Thirty-
six FEP patients underwent treatment using antipsychotic
medication (two refused) and were included in the follow-up
analysis. History of antipsychotic medication was collected from
the reviews of patients’ medical charts. Patients were treated
with various antipsychotic medications according to what was
clinically indicated, and treatments changed over the course of
the 7 months interval. During the follow-up period, patients
received either atypical (n= 24), typical (n= 1) ormixed (n= 11)
antipsychotic medication; the mean theoretical chlorpromazine
daily dose equivalent (Gardner et al., 2010) range was 80–640.
Twenty-eight patients were treated only with antipsychotics, but
five patients additionally needed mood stabilizers and 6 patients
also received antidepressants or hypnotics.
Thirty-seven mentally healthy subjects participated in the
study as CS, and they were recruited by advertising in the same
geographical area the FEP patients came from. Both patients
and CS were interviewed by experienced psychiatric doctors
in order to avoid the inclusion as controls of subjects with
mental disorders. Exclusion criteria for the control group also
included psychotic disorders among close relatives. The study
was approved by the Ethics Review Committee on Human
Research of the University of Tartu (Estonia) and carried out
in accordance with The Code of Ethics of the World Medical
Association. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. The sample of this
study contains the same participants as our previous study by
Haring et al. (2015).
Procedure
For the FEP patients, general demographic data was recorded at
baseline, and fasting blood samples as well as clinical data were
collected at two time points: on admission and after the follow-
up period (mean duration 7.18 ± 0.73 months). According
to our study protocol patients were re-examined after time
interval which comprised of the period what was needed for
symptom remission and after that followed an additional 6-
months period while patients took their medications steadily.
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Psychotic symptoms severity was identified using the Positive
and Negative Syndrome Scale (PANSS) (Kay et al., 1987) positive
symptom subscale. Blood samples and demographic data from
CS were collected cross-sectionally.
Blood Collection and Clinical Laboratory
Measurements
Blood samples of the participants were collected between 09:00
and 11:00 a.m. Blood (5 ml) was sampled using anticoagulant-
free tubes and kept for 1 h at 4◦C (for platelet activation) before
serum was isolated (centrifugation at 2000 rpm for 15min at
4◦C). Serum was kept at−20◦C before testing.
Measurement of Metabolites in Serum
Samples
Serum levels of taurine and spermine were determined with
the AbsoluteIDQTM p180 kit (BIOCRATES Life Sciences
AG, Innsbruck, Austria) using the flow injection analysis
tandem mass spectrometry (FIA-MS/MS) as well as liquid
chromatography (LC-MS/MS) technique on a QTRAP
4500 mass-spectrometer (Sciex, USA). All measurements
were performed as described in the manufacturer’s kit
manual. Identification and quantification of the metabolites
were achieved using multiple reaction monitoring (MRM)
along with internal standards. Calculations of metabolite
concentrations were automatically performed by MetIDQTM
software (BIOCRATES Life Sciences AG). The validation of
metabolomic and cytokine/growth factor measurements are
presented in the Supplementary Material section.
Statistical Analyses
Group differences with regard to demographic measurements
were analyzed using the t-test, or Chi-square test. The application
of Shapiro-Wilk tests indicated that at the group level, values of
taurine and spermine were not normally distributed (p < 0.05).
Mann-Whitney U-test was applied to compare the raw data of
two independent samples (FEP patients before treatment and CS)
and a Wilcoxon signed rank test to compare the two dependent
samples (FEP patients pre- and post-treatment condition).
Spearman’s rank correlation analysis determined the
relationship between serum biomarkers as well as markers and
patients’ disease symptom scores. GLM was used to demonstrate
biomarker levels differences between antipsychotic-naïve
FEP patient and CS. To establish treatment effects to serum
biomarker levels, GLM between the groups (FEP patients after 7
months treatment with antipsychotics compared to CS) as well
as between-subjects (GLM: repeated measures) were utilized.
Categorical (disease, gender, smoking status) and continuous
(age) covariates were used in the GLM to compare biomarker
levels (dependent variables). To study within-subjects differences
in biomarker levels, difference between pre- and post-treatment
condition was used as independent variable. Because GLM
analyses required normally distributed data, biomarker values
were log10-transformed to approximate normality.
In our previous study (Haring et al., 2015) among the same
participants, we found that antipsychotic-naïve FEP patients
demonstrated significantly elevated levels of EGF (Z = 6.67,
p < 0.001), IL-6 (Z = 3.17, p < 0.002), and IL-4 (Z = 3.17,
p < 0.002), and reduced value of IL-1β (Z = 3.01, p < 0.003)
compared to CS. Moreover, in the same study (Haring et al.,
2015) we found that 7 months treatment with antipsychotics
had significant effect on EGF (Z = 5.16, p < 0.001), IL-2
(Z = 4.78, p < 0.001), IL-4 (Z = 2.88, p = 0.004), and IL-6
(Z = 3.34, p< 0.001) levels. To establish the effects of the disease
and treatment condition on the taurine, spermine as well as
abovementioned inflammatory markers and growth factor levels,
we simultaneously entered these log10-transformed biomarker
levels into the GLM.
The statistical analyses were performed using Statistica
software (StatSoft Inc., 12th edition) for Windows (StataCorp,
2011). All statistical tests were two-sided, p< 0.05 was considered
to be statistically significant.
RESULTS
General Description of the Study Groups
There were no statistically significant differences between FEP
patients and CS in terms of age [t(73) = 0.49, p = 0.62], and
gender [χ2(1) = 1.08, p = 0.30]. In addition, the differences in
tobacco use (8 patients [21.1%] vs. 7 controls [18.9%]) was not
statistically significant [χ2(1) = 0.05, p = 0.82]. As expected,
there was a statistically significant 7 months treatment effect on
the positive psychotic symptoms (Wilcoxon signed rank test, Z
= 5.16, p < 0.000001), measured by PANSS positive symptom
score (median = 29, range 18–43 during the recruitment, and
median= 12, range 7–26, at the follow-up period).
Biomarker Level Differences among
Antipsychotic-Naïve FEP Patients and
Control Subjects
First, the metabolomic measurements demonstrated a robust
elevation of taurine (Z = 5.79, p < 0.000001) in antipsychotic-
naïve FEP patients compared to CS (Table 1). The levels of
spermine were also significantly increased (Z = 3.20, p < 0.001)
in the patients group (at baseline) compared to CS; however, this
elevation was not as prominent as in the case of taurine (Table 1).
Spearman rank correlation analyses revealed significant
relationships between taurine and spermine (r = 0.68, p <
0.000001), taurine and EGF (r = 0.63, p < 0.000001), as well as
less pronounced correlations between taurine and IL-4 (r = 0.24,
p < 0.05), and taurine and IL-1ß (r = −0.28, p < 0.05) when all
the participants were taken into account. In addition, spermine
was significantly correlated with EGF (r = 0.37, p< 0.001).
In the next step, multivariate GLM analysis elucidated that
predominantly levels of taurine (p < 0.000001) and EGF
(p < 0.000001) were significantly elevated in antipsychotic-
naïve FEP patients compared to CS group. However, patients
also demonstrated higher levels of IL-6 (p < 0.0003) and IL-
4 (p < 0.0007) compared to CS. A statistical analysis of the
overall difference between the groups is shown in Table 2.
Age, gender and smoking status were not significant predictors
to differentiate biomarker levels between the groups in our
study.
When only one predictor (disease) was used to differentiate
the combination of taurine, EGF, IL-4, and IL-6 serum levels
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TABLE 1 | Comparisons of taurine and spermine levels between the first episode psychosis patients at baseline (FEPb) and healthy control subjects (HC)
as well as FEP patients at baseline (FEPb) and after 7 months of treatment (FEPf) with antipsychotics.
CS Median FEPb Median FEPf Median Z-value
a p-valuea Z-valueb p-valueb
Biomarkers (min–max) (pg/mL) (min–max) (pg/mL) (min–max) (pg/mL)
Taurine 46.30 76.45 46.60 5.79 <0.000001 5.07 <0.000001
(25.80–78.70) (32.40–172.00) (28.20–119.00)
Spermine 0.23 0.27 0.19 3.20 0.001 2.98 0.003
(0.16–0.28) (0.17–0.43) (0.16–0.27)
Z-adjusted valuesa according to Mann-Whitney U-test (FEPb compared to CS). Z-values
b according to Wilcoxon Matched Pairs Test (FEPb compared to FEPf ).
TABLE 2 | Regression coefficients (ß) and significance values of
log10-transformed biomarker levels with disease.
Biomarkers ß ß (95% CI) t-value p-value
AMINO ACID DERIVATIVES
Taurine 0.65 0.46−0.83 7.04 < 0.000001
Spermine 0.23 −0.01–0.47 1.88 0.06
GROWTH FACTOR
EGF 0.81 0.65−0.96 10.67 < 0.000001
PRO-INFLAMMATORY CYTOKINES
IL-1ß −0.25 −0.49–(−0.01) −2.05 0.05
IL-2 0.13 −0.12−0.38 1.06 0.29
IL-4 0.41 0.18−0.64 3.58 0.0007
IL-6 0.43 0.20−0.65 3.80 0.0003
CI, Confidence intervals; EGF, epidermal growth factor; IL-1ß, IL-2, IL-4, IL-6, interleukins.
between antipsychotic-naïve FEP patients and CS, a robust main
effect of the disease emerged [F(4, 69) = 36.17, p < 0.000001,
partial eta2 = 0.68].
Antipsychotic Treatment Effect on
Biomarker Levels among FEP Group
After 7-months antipsychotic treatment, FEP patients’ taurine
and spermine serum concentrations showed a significant
decrease (Wilcoxon signed rank test, Z = 5.07, p< 0.000001 and
Z = 2.98, p = 0.003, respectively) compared with pre-treatment
levels (Table 1).
In further analyses we evaluated the simultaneous impact of
treatment on taurine and spermine as well as on EGF, IL-1ß, IL-2,
IL-4, and IL-6 (growth factor and cytokines which concentrations
were from our previous study (Haring et al., 2015) known to be
dependent on antipsychotic treatment) levels. Repeatedmeasures
GLM was performed to compare the main effect of the 7-
months antipsychotic treatment on the concentration of serum
biomarkers. A powerful decrease over time was detected in the
serum levels of taurine (p < 0.000001), EGF (p < 0.000001)
and IL-2 (p < 0.000001). In addition, serum concentrations of
IL-4 (p < 0.007), IL-6 (p < 0.008), and spermine (p = 0.02)
demonstrated a significant reduction. All effects of the treatment
are summarized in Table 3. While a combination of significantly
changed biomarker levels were used in the repeated measure
GLM, the size of the treatment effect (partial eta2) was 0.73,
[F(6, 64) = 29.34, p< 0.000001].
TABLE 3 | Regression coefficients (ß) and significance values of
log10-transformed biomarker levels in first episode patients group before
treatment compared to biomarker values measured after 7 months of
treatment with antipsychotics.
Biomarkers ß ß (95% CI) t-value p-value
AMINO ACID DERIVATIVES
Taurine 0.63 0.44–0.82 6.66 < 0.000001
Spermine 0.28 0.05–0.51 2.39 0.02
GROWTH FACTOR
EGF 0.78 0.63–0.93 10.27 < 0.000001
PRO-INFLAMMATORY CYTOKINES
IL-1ß 0.11 −0.13–0.35 0.92 0.36
IL-2 0.57 0.37–0.77 5.72 < 0.000001
IL-4 0.32 0.09–0.55 2.78 0.007
IL-6 0.31 0.08–0.54 2.72 0.008
CI, Confidence intervals; EGF, epidermal growth factor; IL-1ß, IL-2, IL-4, IL-6, interleukins.
Furthermore, to evaluate the FEP patients’ post-treatment
status with regard to biomarker levels compared to CS (adjusted
for age, gender and smoking status), GLM was performed. As
seen from Table 4, the antipsychotic treatment reversed the
elevated values of taurine and spermine as well as the levels
of EGF, IL-4, and IL-6 to the levels comparable with CS.
Interestingly, after 7 months of treatment with antipsychotics,
FEP patients demonstrated significantly lower levels of IL-1ß and
IL-2 compared to CS.
DISCUSSION
The present study demonstrated that the serum levels of taurine
were significantly increased in antipsychotic-naïve FEP patients.
This change was comparable to that established for EGF in our
previous study (Haring et al., 2015). By contrast, the alteration of
another biomarker spermine, mediating some effects of taurine
(Motawi et al., 2007; Chan et al., 2013), was less pronounced in
these FEP patients. These findings are in accordance with the
research performed by Bjerkenstedt et al. (1985) and Samuelsson
et al. (2013) demonstrating a significant increase of taurine in
patients suffering from SCZ. Bjerkenstedt et al. (1985) performed
the study in antipsychotic-free patients, whereas the study of
Samuelsson et al. (2013) was conducted in patients under
treatment with antipsychotic drugs. However, neither of these
studies engaged antipsychotic-naïve FEP patients. Therefore, the
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TABLE 4 | Regression coefficients (ß) and significance values of
log10-transformed biomarker levels in first episode patients group after 7
months of treatment with antipsychotics compared to control subjects.
Biomarkers ß ß (95% CI) t-value p-value
AMINO ACID DERIVATIVES
Taurine 0.09 −0.17–0.34 0.69 0.50
Spermine −0.04 −0.29–0.21 −0.31 0.76
GROWTH FACTOR
EGF −0.05 −0.30–0.20 −0.40 0.69
PRO-INFLAMMATORY CYTOKINES
IL-1ß −0.33 −0.57–(−0.09) −2.76 0.008
IL-2 −0.49 −0.71–(−0.28) −4.55 0.00003
IL-4 0.10 −0.15–0.35 0.81 0.42
IL-6 0.22 −0.03–0.47 1.79 0.08
CI, Confidence intervals; EGF, epidermal growth factor; IL-1ß, IL-2, IL-4, IL-6, interleukins.
present study underlines that elevation of taurine is already
present in the early stage of SCZ manifestation. It is remarkable
that taurine displayed a significant positive correlation with EGF
in FEP patients. The relation of spermine to EGF was markedly
weaker compared to its interaction with taurine. GLM supported
a strong association of taurine and EGF with the disease in
antipsychotic-naïve FEP patients group.
Existing evidence shows that EGF and taurine are implicated
in the regulation of oxidative stress (Chen et al., 2012; Nagano
et al., 2015) and activity of NMDA receptors (Chan et al.,
2015; Tang et al., 2015). It is apparent that both EGF and
taurine affect the formation of reactive oxidative species (Cha
et al., 2000; Zhang et al., 2014). On the other hand, the
redox status has been shown to play a role in the regulation
of NMDA receptors (Hashimoto, 2014). Moreover, recent
studies demonstrate that both EGF and taurine influence the
GluN2B subunit of NMDA receptors (Chan et al., 2015; Tang
et al., 2015). Therefore, one could speculate that the elevated
levels of EGF and taurine in antipsychotic-naïve FEP patients
may reflect the corrupted function of NMDA receptors. It
is important to underline that both biomarkers penetrate the
blood-brain barrier (Pan and Kastin, 1999; Salimäki et al.,
2003) and, therefore, peripherally circulating molecules may
potentially interact with NMDA receptors in the brain. It
is well known that the blocking of NMDA receptors with
antagonists like ketamine induces psychotic symptoms in healthy
volunteers and causes exacerbation of psychotic symptoms in
patients suffering from SCZ (Lahti et al., 2001). Therefore,
one could suggest that the elevation of taurine and EGF
may reflect suppressed function of NMDA receptors in FEP
patients. Moreover, the gene determining the GluN2A subunit
of NMDA receptors and the gene determining serine racemase,
an enzyme that generates NMDA receptor co-agonist D-serine,
were determined to be among the risk genes for SCZ (Ripke et al.,
2014).
Treatment with antipsychotic drugs ameliorated clinical
symptoms in FEP patients. Besides that the treatment reduced
the upregulated values of taurine and spermine to the levels
established for CS. This positive change is similar as determined
for several inflammatory and growth factors [EGF, IL-2,
IL-4, IL-6, vascular endothelial growth factor (VEGF) and
interferon-gamma (IFN-γ)] in our previous study (Haring
et al., 2015). The decrease of EGF and taurine was in line
with the decline of PANSS positive symptom score. The
reduction of spermine was also in significant correlation
with taurine and EGF. It is important to underline that
antipsychotic treatment reduced clinical symptoms, but also
reversed the levels of EGF, taurine and spermine to the
level of CS. Taking into account the role of taurine and
EGF in the regulation of oxidative stress and activity of
NMDA receptors one could suggest that antipsychotic treatment
restored the function of NMDA receptors impaired by FEP.
Application of GLM also underlines that the reduction of EGF
and taurine levels reflects the positive effect of antipsychotic
drugs.
To the best of our knowledge there are no available
studies examining the covariation of taurine, spermine, EGF
and inflammatory biomarkers in antipsychotic-naïve FEP
patients compared to CS, and establishing impact of long-term
antipsychotic drug therapy on simultaneous alterations of above-
mentioned biomarkers. Our data emphasizes the idea that the
peripheral biomarkers can be used to detect mental illness. The
discovery of novel diagnostic, prognostic or therapeutically useful
biomarkers is of immense importance for the understanding
of the underlying physiopathology of SCZ. Unfortunately, a
particular biomarker with ideal specificity and sensitivity is
difficult to find, and one potential solution is to use the
combinational power of different biomarkers. It is believed that
by integrating potential biomarkers into drug development and
clinical use, a more personalized approach to patients could
ultimately be adopted.
Some limitations also need to be acknowledged. First, we
collected blood samples from CS at one point in time and did
not control their biomarker levels after the same time interval as
was done for FEP patients. Second, during the re-evaluation, we
recruited patients who were receiving antipsychotic treatment,
and we demonstrated antipsychotic treatment effects on the
levels of taurine, spermine, EGF and inflammatory markers
in FEP patients group. While different drugs have different
affinities for mono-aminergic receptors, they may also have
a different impact on biomarkers’ levels. However, because
of our relative small sample size and the naturalistic study
design we could not establish direct effects of any specific
active substance on the measured biomarkers. Additional results
from larger samples of individuals with FEP are required to
confirm and expand our results in terms of specific antipsychotic
drug, dosage and treatment duration. Furthermore, FEP studies
suggest that antipsychotics may not be a major contributor
to peripheral biomarker levels (Di Nicola et al., 2013) and
changes in serum levels of biomarkers found in patients with
psychotic disorder could be part of the disease pathology rather
than a direct change resulting from treatment (Pillai et al.,
2015).
In conclusion, we established a significant co-upregulation
of taurine and EGF in antipsychotic-naïve FEP patients. This
change probably reflects a relationship between FEP and
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impaired function of NMDA receptors. Antipsychotic treatment
was associated with the reduction of positive symptoms and
with the return of levels of EGF and taurine to that of
established for CS. Therefore, one could suggest that long-term
antipsychotic treatment tends to modify the function of NMDA
receptors.
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